MorphoSys Acquires Lanthipeptide Technology from Lanthio Pharma
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Acquires Lanthipeptide Technology from Lanthio Pharma
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) and Lanthio
Pharma today announced the acquisition of Lanthio Pharma's lanthipeptide
technology, which will be used for drug discovery by MorphoSys. The acquisition
was triggered by MorphoSys exercising an option within an ongoing collaboration
and option agreement between the two companies. By exercising the option,
MorphoSys takes over the lanthipeptide technology and all related intellectual
property. Lanthio Pharma will continue to focus on building its portfolio of
selected lanthipeptide drugs and will participate financially in MorphoSys's
exploitation of the technology. Financial details were not disclosed.
"Lanthipeptides can become a complementary addition to our therapeutic antibody
pipeline and will add more diversity to our drug discovery and development
approaches," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys
AG. "The decision to acquire this technology was made following a feasibility
study to establish high quality and diverse lanthipeptide-based libraries. This
brings us closer to adding members of this class of stabilized peptides to our
drug portfolio."
As part of its innovation capital initiative, MorphoSys entered a collaboration
and option agreement with Lanthio Pharma in November 2012, which included an
equity investment as part of the company's Series A financing round.
"Today's news marks an important step for our innovation capital initiative. The
joint collaboration on a broader lanthipeptide platform has opened up an
interesting opportunity to create further value for both MorphoSys and our
partner," commented Jens Holstein, Chief Financial Officer of MorphoSys. "We
will continue with this initiative and will seek other opportunities to invest
and collaborate selectively with start-ups and smaller biotechs."
Dr. Gert Moll, Chief Scientific Officer of Lanthio Pharma commented: "Great
synergies between our companies have resulted in a very successful
collaboration. We are confident that MorphoSys will be able to further exploit
the great potential of our technology platform by bringing more lanthipeptide
drugs into the clinic."
Lanthipeptides comprise a novel class of therapeutics with high target
selectivity and improved drug-like properties. Lanthio Pharma's approach can be
used to identify peptides which are selective for a specific disease target and
to stabilize them in their optimal structural conformation for receptor binding.
The high specificity can open up new therapeutic applications, potentially
providing drugs for indications classically not targeted with antibodies. In
addition to intravenous administration, therapeutic plasma levels of
lanthipeptides can potentially be achieved via oral, pulmonary or subcutaneous
delivery.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 80 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®
and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary
of MorphoSys AG.
About Lanthio Pharma:
Lanthio Pharma is a privately held drug discovery company that applies its
proprietary lanthionine-peptide technology to the discovery of novel peptide
therapeutics with longer half-life and high receptor selectivity.
Lanthio Pharma is building a pipeline of therapeutic lanthipeptide drugs against
diseases of high medical interest, including fibrosis, cardiovascular diseases,
multiple sclerosis and cancer.
Constrained peptides like lanthipeptides are an emerging compound class which
offers the potential to address many types of target and disease categories,
currently beyond reach for therapeutic proteins or small molecules. The
technology of Lanthio Pharma includes a proprietary bacterial display library
capability, which allows construction of focused or randomized libraries of
lanthipeptides that can be screened against disease targets of interest.
MorphoSys AG has obtained the rights to commercialize Lanthio's technology.
Lanthio Pharma is funded by Inkef Capital, BioGeneration Ventures, MorphoSys and
RUG Holding.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Mario Brkulj
Associate Director Corporate Communications & IR
Alexandra Goller
Specialist Corporate Communications & IR
Jessica Rush
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors(at)morphosys.com
Lanthio Pharma
Michiel Lodder, PhD
VP Business Development
Tel: +31 (0)6 50 21 1329
lodder(at)lanthiopharma.com
Media Release (PDF):
http://hugin.info/130295/R/1862848/653606.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire
[HUG#1862848]
Unternehmensinformation / Kurzprofil:
Datum: 15.10.2014 - 07:31 Uhr
Sprache: Deutsch
News-ID 344037
Anzahl Zeichen: 7495
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 167 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Acquires Lanthipeptide Technology from Lanthio Pharma"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
